We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
101 hedge funds and large institutions have $103M invested in Lineage Cell Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,476% more call options, than puts
Call options by funds: $268K | Put options by funds: $17K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
4.64% less ownership
Funds ownership: 42.95% → 38.31% (-4.6%)
8% less funds holding
Funds holding: 110 → 101 (-9)
9% less capital invested
Capital invested by funds: $112M → $103M (-$9.71M)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
Holders
101
Holders Change
-9
Holders Change %
-8.18%
% of All Funds
1.7%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
20
Increased
18
Reduced
24
Closed
28
Calls
$268K
Puts
$17K
Net Calls
+$251K
Net Calls Change
-$21K
Top Buyers
| 1 |
LCM
Laurion Capital Management
New York
|
+$3.19M |
| 2 |
Millennium Management
New York
|
+$1.11M |
| 3 |
RA
Raffles Associates
New York
|
+$823K |
| 4 |
E
Ergoteles
New York
|
+$730K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$501K |
Top Sellers
| 1 |
BlackRock
New York
|
-$7.98M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.2M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.35M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.09M |
| 5 |
JP Morgan Chase
New York
|
-$782K |
